Response Biomedical to develop RAMP quantitative immuno-chromatographic test prototype by year end.
This article was originally published in The Gray Sheet
Executive Summary
RESPONSE BIOMEDICAL RAMP TEST PROTOTYPE will be developed by the end of this year, the firm said at a recent investment meeting. The Rapid Antigen Measurement Platform quantitative immunodiagnostic test technology under development for the point-of-care sector is "beyond proof of concept" and is projected to be on the market "within two years," Response President David Gabrilska stated at an Aug. 12 session of the Medical Investments Northwest conference in Seattle.